• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Revisiting the safety profile of tenofovir alafenamide: methodological reflections on real-world data.

作者信息

El-Kassas Mohamed, AlNaamani Khalid M

机构信息

Endemic Medicine Department, Faculty of Medicine, Helwan University, Ain Helwan, Cairo, 11795, Egypt.

Department of Medicine, Division of Gastroenterology and Hepatology, The Medical City for Military and Security Services, Muscat, Oman.

出版信息

Hepatol Int. 2025 Apr 21. doi: 10.1007/s12072-025-10829-z.

DOI:10.1007/s12072-025-10829-z
PMID:40259190
Abstract
摘要

相似文献

1
Revisiting the safety profile of tenofovir alafenamide: methodological reflections on real-world data.重新审视替诺福韦艾拉酚胺的安全性：关于真实世界数据的方法学思考
Hepatol Int. 2025 Apr 21. doi: 10.1007/s12072-025-10829-z.
2
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trial.一种每年一次的替诺福韦艾拉酚胺硅酮皮下植入剂在南非女性中的安全性、耐受性和药代动力学：一项分为两部分的、随机、安慰剂对照、双盲、首次人体1期试验。
Lancet HIV. 2025 Aug;12(8):e556-e567. doi: 10.1016/S2352-3018(25)00079-7. Epub 2025 Jun 27.
3
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.在病毒学抑制的慢性乙型肝炎合并肾或肝功能损害患者中换用替诺福韦艾拉酚胺：一项开放标签、多中心、2 期研究的第 96 周最终结果。
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):718-733. doi: 10.1016/S2468-1253(24)00096-7. Epub 2024 Jun 17.
4
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.多替拉韦与拉米夫定维持治疗对比比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺用于HIV感染者（PASO-DOBLE）：一项随机、多中心、开放标签、非劣效性试验的48周结果
Lancet HIV. 2025 Jul;12(7):e473-e484. doi: 10.1016/S2352-3018(25)00105-5. Epub 2025 Jun 7.
5
Real World Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Liver Transplant Recipients.肝移植受者从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺的真实世界疗效和安全性
Transpl Infect Dis. 2025 Jul 2:e70068. doi: 10.1111/tid.70068.
6
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.使用丙酚替诺福韦进行早期抗病毒治疗以预防慢性乙型肝炎且病毒血症为中度或高度的成人发生严重临床不良事件（ATTENTION）：一项随机对照试验的中期结果
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):295-305. doi: 10.1016/S2468-1253(24)00431-X. Epub 2025 Feb 3.
7
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和替诺福韦二吡呋酯用于 HIV-1 暴露前预防的长期安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的第 96 周结果。
Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0.
8
Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?对于肾脏而言，丙酚替诺福韦比富马酸替诺福韦二吡呋酯更安全吗？
AIDS Rev. 2016 Oct-Dec;18(4):184-192.
9
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis.替诺福韦艾拉酚胺在高脂血症和心血管疾病背景下的安全性：一项全国性分析。
Hepatol Int. 2025 Mar 8. doi: 10.1007/s12072-025-10809-3.
10
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.在TANGO研究中，至第196周，从基于替诺福韦艾拉酚胺的三药或四药方案转换为多替拉韦/拉米夫定二药方案的持久疗效。
J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003395.

本文引用的文献

1
Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors.肝脏免疫相关不良事件提高了接受免疫检查点抑制剂治疗的恶性肿瘤患者的总生存率。
Hepatol Int. 2025 Apr 8. doi: 10.1007/s12072-025-10825-3.
2
Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B.替诺福韦酯与恩替卡韦：对慢性乙型肝炎患者血脂谱和心血管结局的影响
J Med Virol. 2025 Feb;97(2):e70187. doi: 10.1002/jmv.70187.
3
The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.降脂治疗对脂质相关残余风险因素的影响：一项前瞻性研究。
Lipids Health Dis. 2024 May 7;23(1):134. doi: 10.1186/s12944-024-02078-0.
4
Do Biobank Recall Studies Matter? Long-Term Follow-Up of Research Participants With Familial Hypercholesterolemia.生物样本库召回研究重要吗？对家族性高胆固醇血症研究参与者的长期随访
Front Genet. 2022 Jul 19;13:936131. doi: 10.3389/fgene.2022.936131. eCollection 2022.
5
Big Data and Predictive Analytics: Recalibrating Expectations.大数据与预测分析：重新校准期望
JAMA. 2018 Jul 3;320(1):27-28. doi: 10.1001/jama.2018.5602.